Home

venBio Global Strategic GP II, Ltd.

CIK 1729408 · last filed 2022-05-12

venBio Global Strategic GP II, Ltd. is a corporate insider who has filed 6 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing shows the insider sold $8.4M of CMPI on May 12, 2022. Across all open-market trades the lifetime net is −$74.5M, making them a net seller over the disclosed history. The firm reports its address in San Francisco, CA. 28 SEC filings were submitted jointly with Robert J Adelman.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

6

Lifetime Open-Market Net

-$74.55M

Filer Profile

Reported Address
1700 OWENS STREET
SUITE 595
SAN FRANCISCO, CA 94158
Phone
(415) 522-0100
State of Incorporation
Cayman Islands
Related Filers
Robert J Adelman — 28 joint filings, latest 2022-05-17
venBio Global Strategic Fund II L.P. — 28 joint filings, latest 2022-05-17
venBio Global Strategic GP II, L.P. — 28 joint filings, latest 2022-05-17
COREY S GOODMAN — 26 joint filings, latest 2022-05-17
venBio Global Strategic GP, Ltd. — 2 joint filings, latest 2020-07-21
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Checkmate Pharmaceuticals, Inc. (CMPI) Delisted 10%+ Owner 2,287,580 $10.50 $24.02M -$15.10M 2 2022-05-12
Akero Therapeutics, Inc. (AKRO) Delisted 10%+ Owner 3,160,319 $54.65 $172.71M -$59.45M 4 2020-03-06

Recent Filings

6 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-05-12 Checkmate Pharmaceuticals, Inc. (CMPI) Delisted Sell (S) −804,505 -$8.36M EDGAR
2022-04-26 Checkmate Pharmaceuticals, Inc. (CMPI) Delisted Sell (S) −648,905 -$6.74M EDGAR
2020-03-06 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −229,750 -$5.46M EDGAR
2020-03-03 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −108,990 -$2.47M EDGAR
2020-01-14 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −2,470,000 -$49.97M EDGAR
2020-01-10 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −78,385 -$1.56M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.